Get the Stockscreener App
532.53
1.67%
-9.07
Pre-market:
531.00
-1.53
-0.29%
United Therapeutics Corp stock is traded at $532.53, with a volume of 427.90K.
It is down -1.67% in the last 24 hours and up +5.74% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$541.60
Open:
$534.65
24h Volume:
427.90K
Relative Volume:
0.97
Market Cap:
$23.34B
Revenue:
$3.18B
Net Income/Loss:
$1.33B
P/E Ratio:
19.09
EPS:
27.9001
Net Cash Flow:
$1.04B
1W Performance:
+1.05%
1M Performance:
+5.74%
6M Performance:
+23.08%
1Y Performance:
+71.33%
1-Day Range:
$530.82
$541.16
1-Week Range:
$517.59
$549.50
52-Week Range:
$266.98
$549.50
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
532.53 | 23.34B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
18.06 | 57.06B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.63 | 49.23B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.78 | 34.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics director Tommy G Thompson sells $1.1m in stock By Investing.com - Investing.com South Africa
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com
Rothblatt, United Therapeutics CEO, sells $5m in stock By Investing.com - Investing.com Australia
Rothblatt, United Therapeutics CEO, sells $5m in stock - Investing.com
United Therapeutics stock hits all-time high at 548.43 USD - Investing.com
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
Rothblatt of United Therapeutics sells $5m in UTHR stock - Investing.com
United Therapeutics CFO Edgemond sells $5.27 million in UTHR stock - Investing.com
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers - TradingView
Rothblatt, United Therapeutics CEO, sells $4.9m in UTHR stock By Investing.com - Investing.com India
Rothblatt, United Therapeutics CEO, sells $4.9m in UTHR stock - Investing.com
[144] UNITED THERAPEUTICS Corp SE... | UTHR SEC FilingForm 144 - Stock Titan
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares under 10b5-1 plan - Stock Titan
UTHR (UTHR): Judy Olian to sell 200 shares under Form 144 notice - Stock Titan
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart
UTHR: Wells Fargo Raises Price Target for United Therapeutics | UTHR Stock News - GuruFocus
Dip Buying: Can United Therapeutics Corporation grow without dilution2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in United Therapeutics Corp. (UTHR) - Stock Titan
Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
United Therapeutics CEO Rothblatt sells $5m in UTHR stock - Investing.com UK
United Therapeutics CEO Rothblatt sells $5m in UTHR stock By Investing.com - Investing.com South Africa
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares under plan - Stock Titan
United Therapeutics (UTHR) EVP sells 8,300 shares after option exercise - Stock Titan
UTHR affiliate to sell 8,300 shares via option exercise (NASDAQ: UTHR) - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Biotech Stocks Worth WatchingMarch 18th - MarketBeat
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics (UTHR) COO exercises RSUs; 14,706 shares withheld for taxes - Stock Titan
United Therapeutics (UTHR) CFO exercises RSUs, shares withheld for taxes - Stock Titan
United Therapeutics (UTHR) legal chief vests 16,691 RSUs, nets 45,172 shares - Stock Titan
United Therapeutics (UTHR) CEO settles 69,579 RSUs with tax withholding - Stock Titan
United Therapeutics (UTHR) director sells 45 shares under 10b5-1 plan - Stock Titan
United Therapeutics Corporation $UTHR Holdings Lifted by L2 Asset Management LLC - MarketBeat
Assessing United Therapeutics (UTHR) Valuation After TETON-2 Tyvaso Data And New US$2b Buyback Program - simplywall.st
Rothblatt of United Therapeutics sells $5.1 million in UTHR stock - Investing.com
Judy Olian sells 400 UTHR shares across March transactions (UTHR) - Stock Titan
United Therapeutics CEO Martine A. Rothblatt Executes Stock Sales - TradingView
United Therapeutics (UTHR) director sells 200 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) CEO pre-planned option exercise and 9,500-share sale - Stock Titan
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,984 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells $276,054.84 in Stock - MarketBeat
Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It - MSN
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential - Yahoo Finance
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Van ECK Associates Corp Purchases 29,297 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):